Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-31
2007-07-31
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S309000
Reexamination Certificate
active
11047229
ABSTRACT:
A new class of diketo acids constructed on nucleobase scaffolds, designed as inhibitors of HIV replication through inhibition of HIV integrase, is described. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS and ARC, either as the compounds, or as pharmaceutically acceptable salts, with pharmaceutically acceptable carriers, used alone or in combination with antivirals, immunomodulators, antibiotics, vaccines, and other therapeutic agents. Methods of treating AIDS and ARC and methods of treating or preventing infection by HIV are also described.
REFERENCES:
patent: 6492423 (2002-12-01), Sergio et al.
patent: 6620841 (2003-09-01), Fujishita et al.
patent: 6645956 (2003-11-01), Fujishita et al.
patent: 6803374 (2004-10-01), Priestley et al.
patent: 6803378 (2004-10-01), Walker et al.
patent: 7098201 (2006-08-01), Fujishita et al.
patent: 2003/0207922 (2003-11-01), Neuner et al.
patent: WO 00/06529 (2000-02-01), None
Vasu Nair Rev, Med. Viro. 12;179-193, 2002.
Fauci, Science 239, 617-622 (1988).
Katz & Skalka, Annu. Rev. Biochem. 63, 133-173 (1994).
Frankel, Annu. Rev. Biochem. 67, 1-25 (1998).
De Clercq, J. Med. Chem 38, 2491-2517 (1995).
De Clercq, Clin. Microbiol Rev. 10, 674-693 (1997).
De Clercq, Nature Reviews: Drug Discovery 11, 13-25 (2002).
Johnson & Gerber, in “Advances in Internal Medicine” vol. 44, Mosby: St. Louis, 1-40 (2000).
Miller & Hazuda, Current Opinion in Microbiology, 4, 535-539 (2001).
Asante-Appiah & Skalka, Adv. Virus Res., 52, 351-369 (1999).
Nair, in “Recent Advances in Nucleosides: Chemistry and Chemotherapy,” Elsevier Science: Netherlands, 149-166 (2002).
De Clercq, Intl. J. Biochem, CellBiol. 36, 1800-1822 (2004).
Nair, Rev. Med. Virol., 12, 179-193 (2002).
Nair, Current Pharmaceutical Design, 9, 2553-2565 (2003).
Esposito & Craigie, Adv. Virus Res. 52, 319-333 (1999).
Chi and Nair, Bioorg. Med. Chem. Letter 14, 4815-4817 (2004).
Taktakkishvilli et al., J. Am. Chem. Soc., 122, 5671-5677 (2000).
Wai et al., “4- Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells,” J. Med. Chem. 43, 4923-4926 (2000).
Pais, G. C. G., et al., “Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors” J. Med. Chem. 45, 3184-3194 (2002).
Marchand, C. jet al., “Structural determinants for HIV-1 integrase inhibition by beta-diketo acids” J. Biol. Chem. 277, 12596-12603 (2002).
Sechi, M. et al., “Design and Synthesis of novel indole beat-diketo acid derivatives as HIV-1 integrase inhibitors. ” J. Med. Chem. 47, 5298-5310 (2004).
Zhang, et al., “Azido-containing aryl beta-keto acid HIV-1 integrase inhibitors” Bioorg. Med. Chem. Lett. 13, 1214-1219 (2003).
Grobler, J. A. et al., Proc. Natl. Acad. Sci. U.S.A. 99, 6661-6666 (2002).
Hazuda, D. J. et al., Science 287, 646-650 (2000).
Pannecouque, C. et al., Current Biology 12, 1169-1177 (2002).
Chi Guochen
Nair Vasu
Uchil Vinod R.
Balasubramanian Venkataraman
Coleman Henry D.
Sapone William J.
Sudol R. Neil
University of Georgia Research Foundation Inc.
LandOfFree
Diketo acids with nucleobase scaffolds: anti-HIV replication... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diketo acids with nucleobase scaffolds: anti-HIV replication..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diketo acids with nucleobase scaffolds: anti-HIV replication... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3752403